Add BrightSurf on Google Email

Intracardiac echocardiography recognized as ‘transformative’ imaging modality in new SCAI position statement

The SCAI position statement highlights the advantages of intracardiac echocardiography (ICE) in improving safety, efficiency, and patient access for structural heart interventions. ICE offers real-time, high-resolution imaging without general anesthesia, streamlining procedures and reducing complications.

SourceSociety for Cardiovascular Angiography and Interventions·JournalJournal of the Society for Cardiovascular Angiography & Interventions·DateOct 7, 2025

AI and omics unlock personalized drugs and RNA therapies for heart disease

A new review in Frontiers in Science calls for a fundamental shift in how heart drugs are discovered and tested using AI, omics, and big data. This approach could drive the development of personalized treatments for cardiovascular disease, which currently relies on broad-brush treatments that don't account for individual variability.

SourceFrontiers·JournalFrontiers in Science·TypeSystematic review·DateOct 7, 2025

Body composition and cardiometabolic risk in children

A repeated cross-sectional study shows that cardiometabolic risk factors in Spanish children have improved over the last 30 years, with decreases in excess weight, lipid parameters, and blood pressure. The study provides valuable insights into the evolution of cardiometabolic risk in children.

SourceJAMA Network·JournalJAMA Network Open·DateOct 2, 2025

SCAI advocates for fairer policies to protect children and adults living with congenital heart disease

The Society for Cardiovascular Angiography & Interventions calls for Medicaid payment parity, fairer valuation of CHD procedures, and new compensation models to support care for children and adults with congenital heart disease. This policy statement aims to improve outcomes by addressing economic inequities in the healthcare system.

New international guideline provides expert guidance for PET imaging of patients with coronary artery disease

A new clinical guideline has been issued for 18F-flurpiridaz PET myocardial perfusion imaging, providing recommendations for patient selection, imaging protocols, and interpretation of results. The guideline aims to enhance diagnostic accuracy and optimize resource utilization for the evaluation of coronary artery disease.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateSep 18, 2025

Major new report sets out how to tackle the ‘profound and lasting impact’ of COVID-19 on cardiovascular health

A major report published by the European Society of Cardiology outlines expert recommendations for diagnosing, treating, and preventing COVID-19-related cardiovascular effects. The report emphasizes the importance of vaccination, cardiac rehabilitation programs, and equal access to services.

SourceEuropean Society of Cardiology·JournalEuropean Journal of Preventive Cardiology·DateSep 17, 2025

Dual antiplatelet therapy is not more effective than aspirin alone after coronary artery bypass grafting

A new study found that dual antiplatelet therapy did not reduce the risk of major adverse cardiovascular events and actually increased the risk of major bleeding in patients with acute coronary syndrome who underwent coronary artery bypass grafting. The 12-month trial results showed no significant difference between DAPT and aspirin al...

SourceEuropean Society of Cardiology·JournalNew England Journal of Medicine·DateSep 5, 2025

Worse outcomes with aspirin in high-risk chronic coronary syndrome patients who require long-term anticoagulation

Adding aspirin to long-term anticoagulation therapy increased the risk of cardiovascular events, death, and major bleeding in patients with chronic coronary syndrome who required anticoagulation. The AQUATIC trial found that aspirin significantly increased all-cause mortality and major cardiovascular events in this high-risk population.

Updated ESC Guidelines put focus on women’s autonomy to make their own reproductive choices about high-risk pregnancies

The updated guidelines focus on a woman's autonomy to make reproductive choices about high-risk pregnancies. They recommend personalized pregnancy-related risk assessment and thorough exploration of maternal preferences as part of the shared decision-making process. The guidance aims to reduce maternal mortality and morbidity by provid...

SourceEuropean Society of Cardiology·JournalEuropean Heart Journal·DateSep 4, 2025

Increasing potassium levels improve outcomes in patients at high risk of ventricular arrhythmia

The POTCAST trial found that increasing potassium levels to the high-normal range significantly reduced the risk of sustained ventricular tachycardia, ICD therapy, unplanned hospitalizations, and all-cause mortality. This benefit was observed across various subgroups, including those with ischemic heart disease and heart failure.

SourceEuropean Society of Cardiology·JournalNew England Journal of Medicine·DateSep 4, 2025

New guidelines for myocarditis and pericarditis aim to improve diagnosis and treatment – and help patients return to exercise and work more quickly

The new guidelines introduce a unifying term for inflammatory myopericardial syndrome and provide easy-to-use flow charts to support medical professionals in diagnosing and treating myocarditis and pericarditis. The recommendations also prioritize patient return to work and exercise, aiming to improve clinical outcomes.

SourceEuropean Society of Cardiology·JournalEuropean Heart Journal·DateSep 4, 2025

New guidance recommends a new approach to assess cardiovascular risk and reach treatment goals for lipid levels

The European Society of Cardiology has published a new update to its guidelines for managing lipid levels in patients to reduce cardiovascular risk. The guidance recommends the use of new cardiovascular risk prediction algorithms, SCORE2 and SCORE2-OP, to help clinicians treat patients with the right medications. Statins are also recom...

SourceEuropean Society of Cardiology·JournalEuropean Heart Journal·DateSep 4, 2025

ESC calls for a cultural shift to deal with the adverse combination of mental health conditions and cardiovascular disease

The European Society of Cardiology recommends systematically screening for mental health symptoms during cardiovascular care and assessing cardiovascular risk in those with mental health conditions. People living with both conditions have worse health outcomes due to the interplay between mental health and cardiovascular disease.

SourceEuropean Society of Cardiology·JournalEuropean Heart Journal·DateSep 4, 2025

Evidence appears supportive for the initiation of SGLT2 inhibitors in patients hospitalised for heart failure

In-hospital initiation of SGLT2 inhibitors did not significantly reduce short-term risk of cardiovascular death or worsening heart failure in patients admitted for heart failure. However, combining trial data shows positive effects of SGLT2 inhibitors on reducing early risk of cardiovascular death or worsening HF and all-cause mortality.

SourceEuropean Society of Cardiology·JournalCirculation·DateSep 4, 2025

Beta-blockers did not reduce cardiovascular events in selected heart attack patients in the REBOOT trial

The REBOOT trial found that beta-blocker therapy had no significant impact on all-cause death, reinfarction, or heart failure admission in patients with myocardial infarction and left ventricular ejection fraction (LVEF) ≥40%. In contrast, a meta-analysis suggests potential benefits for patients with mildly reduced LVEF (40–49%).

SourceEuropean Society of Cardiology·JournalThe Lancet·DateSep 4, 2025